As of April 28, 2026, enGene Therapeutics's top three insider holders are Growth Sponsor Feac I B.V. Forbion (TenPercentOwner, 3.77Mn shares), Growth Opportunities Fund I Cooperatief U.A. Forbion (TenPercentOwner, 3.03Mn shares), Capital Investment Management Inc. Lumira (TenPercentOwner, 1.23Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Growth Sponsor Feac I B.V. Forbion | - | 0 | 3,765,932 | 02 Nov, 2023 |
| De Solidarite Des Travailleurs Du Quebec Fonds | - | 3,036,153 | 0 | 22 Apr, 2024 |
| Growth Opportunities Fund I Cooperatief U.A. Forbion | - | 3,032,430 | 0 | 01 Nov, 2024 |
| Capital Investment Management Inc. Lumira | - | 0 | 1,232,502 | 21 Feb, 2024 |
| Gerald A Brunk | - | 0 | 238,851 | 21 Feb, 2024 |
| Anthony Tzeyew Cheung | Chief Technology Officer | 102,873 | 0 | 20 Mar, 2024 |
| Richard M Glickman | - | 24,675 | 0 | 29 May, 2024 |
| Ronald Harold Wilfred Cooper | Chief Executive Officer | 10,000 | 0 | 01 Oct, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 30 Jan, 2026 | Matthew Ross Boyd | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Jan, 2026 | Jill Buck | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Jan, 2026 | Lee Giguere | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Jan, 2026 | Anthony Tzeyew Cheung | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Jan, 2026 | Ronald Harold Wilfred Cooper | Stock Option (Right to Buy) | A | 801,000 | $0.00 | 801,000 | D | A |
| 30 Jan, 2026 | D. Ryan Daws | Stock Option (Right to Buy) | A | 220,000 | $0.00 | 220,000 | D | A |
| 30 Jan, 2026 | Alexander Julian Nichols | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Jan, 2026 | Joan Connolly | Stock Option (Right to Buy) | A | 195,000 | $0.00 | 195,000 | D | A |
| 30 Sep, 2025 | Hussein Sweiti | Stock Option (Right to Buy) | A | 600,000 | $0.00 | 600,000 | D | A |
| 08 Jul, 2025 | Matthew Ross Boyd | Stock Option (Right to Buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 08 Jul, 2025 | Philip Astley-Sparke | Stock Option (Right to Buy) | A | 45,000 | $0.00 | 45,000 | D | A |
| 08 Jul, 2025 | Jill Buck | Stock Option (Right to Buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 08 Jul, 2025 | William Grossman | Stock Option (Right to Buy) | A | 45,000 | $0.00 | 45,000 | D | A |
| 08 Jul, 2025 | Michael Thomas Heffernan | Stock Option (Right to Buy) | A | 45,000 | $0.00 | 45,000 | D | A |
| 16 Jun, 2025 | Amy Pott | Stock Option (Right to Buy) | A | 400,000 | $0.00 | 400,000 | D | A |
| 16 Jun, 2025 | Richard M Glickman | Stock Option (Right to Buy) | A | 22,500 | $0.00 | 22,500 | D | A |
| 16 Jun, 2025 | Jasper Bos | Stock Option (Right to Buy) | A | 22,500 | $0.00 | 22,500 | D | A |
| 16 Jun, 2025 | Paul J Hastings | Stock Option (Right to Buy) | A | 22,500 | $0.00 | 22,500 | D | A |
| 16 Jun, 2025 | Gerald A Brunk | Stock Option (Right to Buy) | A | 22,500 | $0.00 | 22,500 | D | A |
| 16 Jun, 2025 | Lota S. Zoth | Stock Option (Right to Buy) | A | 22,500 | $0.00 | 22,500 | D | A |